Shape Pharmaceuticals' Other Investors

Shape Pharmaceuticals raised a round of funding on , . Investors include HealthCare Ventures.

Shape Pharmaceuticals is developing SHP-141, a novel, topical HDAC inhibitor, currently in early clinical development, for the treatment of patients with cutaneous T cell lymphoma (CTCL). The developm…

Articles about Shape Pharmaceuticals' Other Investors: